Biomarkers for Detection and Treatment of Barrett's Esophagus
AssigneeThe Johns Hopkins University
InventorsStephen J. Meltzer, Neil Andrew Kalra, Yulan Cheng, Yifan Yang
Life of this patent
Estimating the term…
Abstract
Methods for diagnosing and treating Barrett's esophagus include the identification of biomarker panels.
Claims23
A method of diagnosing and treating for Barrett's esophagus, the method comprising:
- a) assaying a methylation state of a biomarker in a sample obtained from a subject;
- and
- b) diagnosing the subject as having Barrett's esophagus when the methylation state of the biomarker is different than the methylation state of the biomarker assayed in a subject that does not have Barrett's esophagus or in a subject that does not have Barrett's esophageal dysplasia, wherein a methylated biomarker comprises at least one of:
- C9orf50, TBC1D30, SCOC, KCNQ3, cg05548912, cg15711268, NCAM1, STMN3, FLT3, MSC, A1BG, GSG1L, ITGA4, NTNG1, HOXB13, FLI1, TRIM61, FAM218A, BMP3, IRF4, USP44, ZNF736, cg03061682, GRAMD1B, SPX, TM6SF1, cg18991611, cg24171907, cg00720137 or cg24687051;
- thereby, diagnosing and treating a subject.
A method of diagnosing and treating for Barrett's esophagus, the method comprising:
- a) assaying a biomarker profile diagnostic of the subject as having Barrett's esophagus,
- wherein the biomarker profile is different than the biomarker profile assayed in a subject that does not have Barrett's esophagus or in a subject that does not have Barrett's esophageal dysplasia,
- wherein the biomarker profile comprises two or more of:
- C9orf50, TBC1D30, SCOC, KCNQ3, cg05548912, cg15711268, NCAM1, STMN3, FLT3, MSC, A1BG, GSG1L, ITGA4, NTNG1, HOXB13, FLI1, TRIM61, FAM218A, BMP3, IRF4, USP44, ZNF736, cg03061682, GRAMD1B, SPX, TM6SF1, cg18991611, cg24171907, cg00720137 or cg24687051;
- thereby, diagnosing and treating the subject.
A method of detecting and treating a subject suspected of having Barrett's esophagus, the method comprising:
- obtaining a biological sample from an esophagus of the subject;
- determining a biomarker profile in the biological sample, wherein if one or more biomarkers indicative of Barrett's esophagus is detected in the sample, the subject is treated with at least one of:
- removing at least part of the esophagus, esophagectomy, or increasing a frequency of endoscopic surveillance, or chemotherapy.
A kit for diagnosing Barrett's esophagus comprising:
- one or more probes, stains, or antibodies capable of labeling two or more biomarkers selected from the group consisting of C9orf50, TBC1D30, SCOC, KCNQ3, cg05548912, cg15711268, NCAM1, STMN3, FLT3, MSC, A1BG, GSG1L, ITGA4, NTNG1, HOXB13, FLI1, TRIM61, FAM218A, BMP3, IRF4, USP44, ZNF736, cg03061682, GRAMD1B, SPX, TM6SF1, cg18991611, cg24171907, cg00720137 or cg24687051, and any combination thereof.
(canceled)
(canceled)
A biomarker panel for diagnosing and treating a subject with Barrett's esophagus or Barrett's esophageal dysplasia, wherein the biomarker panel consists of biomarkers selected from A1BG, C9orf50, cg00720137, FLI1, GRAMD1B, HOXB13, IRF4, KCNQ3, NTNG1, SPX, TBC1D30, and USP44.
23-27. (canceled)
Dependencies are inferred from the claim text.